Chemodex

Docetaxel

As low as CHF 41.00

In stock

Only %1 left

CDX-D0371-M0055 mgCHF 41.00

CDX-D0371-M02525 mgCHF 122.00

Specifications / Handling

More Information
Product Details
Synonyms	Taxotere®; NSC 628503; RP 56976; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
Product Type	Chemical
Properties
Formula	C₄₃H₅₃NO₁₄
MW	807.88
CAS	114977-28-5
Source/Host Chemicals	Synthetic.
Purity Chemicals	≥97% (HPLC)
Appearance	White to off-white powder.
Solubility	Soluble in DMSO or ethanol.
Identity	Determined by ¹H-NMR.
Declaration	Manufactured by Chemodex.
Other Product Data	Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key	ZDZOTLJHXYCWBA-VCVYQWHSSA-N
Smiles	CC(C)(OC(N[C@H]([C@H](C(O[C@H]1C[C@@]([C@H]([C@@H]([C@@]2(C([C@@H](C3=C1C)O)=O)C)[C@]4([C@@H](C[C@@H]2O)OC4)OC(C)=O)OC(C5=CC=CC=C5)=O)(C3(C)C)O)=O)O)C6=CC=CC=C6)=O)C
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Protect from light and moisture.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Scientific Background Information

Product Description

Anticancer agent. Semisynthetic analog of taxol (paclitaxel). Inhibits microtubule disassembly and inhibits cell replication. Binds to and stabilizes the β−tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest at G2/M and apoptosis. This cytotoxic activity has been widely exploited in suppressing oncogenic proliferation. Displays potent and broad antineoplastic properties, used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Also studied for use as a radiation-sensitizing agent.

Product-specific References

(1) M.C. Bissery, et al.; Cancer Res. 51, 4845 (1991) | (2) R. Bruno & G.J. Sanderink; Cancer Surv. 17, 305 (1993) (Review) | (3) K. Gelmon; Lancet 344, 1267 (1994) (Review) | (4) M.E. Trudeau; Can. J. Oncol. 6, 443 (1996) (Review) | (5) I.A. Avramis, et al.; Anticancer Res. 21, 2281 (2001) | (6) M. Aapro & E. Rowinsky; Anticancer Drugs 12, S1 (2001) (Review) | (7) P.B. Cassidy, et al.; Clin. Cancer Res. 8, 846 (2002) | (8) M.S. Si, et al.; Invest. New Drugs 21, 281 (2003) | (9) B. Ramaswamy & S. Puhalla; Drugs Today 42, 265 (2006) (Review) | (10) H. Hernandez-Vargas, et al.; Cell Cycle 6, 780 (2007) (Review) | (11) H. Ching-Hsia, et al.; Toxicol. Sci. 145, 59 (2015)

Call	+41 61 926 6040
Fax	+41 61 926 6049